BIRC2 and neoplasm: NVP-LCL161 is a first-in-class oral SMAC mimetic that induces degradation of cIAP1 and has demonstrated single-agent activity in human tumor xenograft models, with basal production of TNF-α and NF-κB inhibition as a common mechanism34,35.